Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 6/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590152 | 0.92 | CDC7 (0.43) | MAP2CDC7CCNA2CDK2CCNA1 | |
| SCHEMBL3608210 | 0.90 | DHODH (0.44) | MAP2CDC7CDK2CDK5DYRK1A | |
| SCHEMBL3594823 | 0.88 | CDC7 (0.45) | MAP2CDC7CDK2BTKCLK1 | |
| SCHEMBL15005624 | 0.83 | MAP2 (0.42) | MAP2CDC7CCNA2CDK2CCNA1 | |
| SCHEMBL3603414 | 0.83 | CDC7 (0.43) | CDC7CCNA2CDK2CCNA1CDK5 | |
| SCHEMBL3600494 | 0.79 | CDC7 (0.40) | CDC7CDK2CLK1CDK5DYRK1A | |
| SCHEMBL3598893 | 0.78 | ERN1 (0.47) | MAP2CDC7CDK2CDK5DYRK1A | |
| SCHEMBL3600108 | 0.75 | CDC7 (0.48) | MAP2CDC7CCNA2CDK2CCNA1 | |
| SCHEMBL15005797 | 0.75 | CDC7 (0.39) | MAP2CDC7CCNA2CDK2CCNA1 | |
| SCHEMBL15005240 | 0.72 | CDC7 (0.40) | CDC7CDK2CLK1CDK5DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | claimed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | claimed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | claimed |
| EP-2118102-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-18 | — | — | EP | claimed |
| WO-2008065054-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-05 | — | — | WO | claimed |
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
| EP-2118102-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008065054-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | MAP2 501/4885CDC7 1/4885CCNA2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.